Results showed that N1-ICD levels partially recovered in CLL cells pretreated with SB216763 and then with AKTiX, compared with cells treated with AKTiX alone (n = 6; Fig. 5B), suggesting that reduction in N1-ICD levels by AKT inhibition is mediated by GSK3β activity. The gene discussed is GSK3B; the disease is B-cell chronic lymphocytic leukemia.